PCI recently announced the acquisition of Ajinomoto Althea. How does this acquisition enhance PCI’s sterile fill-finish capabilities and strategy? 

The acquisition of Ajinomoto Althea in San Diego, CA significantly augments PCI’s sterile fill-finish offering in North America. With proven expertise in clinical and commercial supply of sterile vial, prefilled syringe and cartridge filling, this strategic addition expands our capabilities, capacities and technologies, including isolated lines, for the aseptic manufacturing of biologics, including mRNA, mAbs, LNPs, oligonucleotides, peptides, and other complex modalities.